Biocause Pharma(SZ:000627) 2 1 Shi Ji Jing Ji Bao Dao·2025-08-14 13:29Core Viewpoint - *ST Tianmao has faced a series of challenges since 2025, including delayed annual reports, stock price drops, and plans to voluntarily delist, raising concerns about investor rights and company transparency [1][2][4]. Group 1: Disclosure Issues - On April 29, 2025, *ST Tianmao announced it could not release its 2024 annual report and Q1 2025 report on time, citing the need for further information [2]. - The stock price fell to 3.04 yuan per share, marking the largest single-day drop in three months, reflecting investor concerns over the company's disclosure practices [2]. Group 2: Financial Performance and Liquidity Concerns - The company is primarily reliant on its subsidiary, Guohua Life, which is facing significant operational pressures, with a projected loss of 500 million to 750 million yuan for the full year of 2024 [3]. - Guohua Life reported a high surrender payment of 20.6 billion yuan in 2023, with compensation expenses surging to 21.822 billion yuan in the first three quarters of 2024, indicating increasing liquidity risks [3]. Group 3: Delisting Plans - On August 14, 2025, *ST Tianmao announced plans to voluntarily withdraw its A-shares from the Shenzhen Stock Exchange due to significant uncertainties affecting the company [4]. - A shareholder meeting is scheduled for August 25, 2025, to discuss the delisting proposal, with stock trading suspended from August 14, 2025 [4].